Skip Navigation
Skip to contents

JYMS : Journal of Yeungnam Medical Science

Indexed in: ESCI, Scopus, PubMed,
PubMed Central, CAS, DOAJ, KCI
FREE article processing charge
OPEN ACCESS
SEARCH
Search

Author index

Page Path
HOME > Browse Articles > Author index
Search
Min Kyoung Kim 12 Articles
Cephalosporin-induced encephalopathy in patients with hematologic malignancies: a significant concern
Young Seob Park, Min Kyoung Kim, Kyung Hee Lee, Sung Ae Koh, Ji Yoon Jung, Byeong Il Jang, Se-Jin Lee
J Yeungnam Med Sci. 2023;40(Suppl):S137-S141.   Published online November 14, 2023
DOI: https://doi.org/10.12701/jyms.2023.00864
  • 473 View
  • 23 Download
PDF
Immune thrombocytopenia associated with sarcoidosis.
Da Eun Jeong, Min Kyoung Kim, Sung Ae Koh, Kyoung Hee Lee, Joon Hyuk Choi, Young Hoon Hong, Jae Ho Cho, Eun Ju Goo, Myung Soo Hyun
Yeungnam Univ J Med. 2015;32(1):26-30.   Published online June 30, 2015
DOI: https://doi.org/10.12701/yujm.2015.32.1.26
  • 1,957 View
  • 8 Download
AbstractAbstract PDF
Sarcoidosis is a systemic disease of unknown cause involving multiple organs and is characterized by noncaseating granuloma. Immune thrombocytopenia (ITP) is an autoimmune disease characterized by increased peripheral platelet destruction due to the presence of an antibody to the platelet and abnormal platelet production. There is no known pathogenesis that occurs concurrently with ITP and sarcoidosis. However, considering together of 2 known pathogenesis, abnormal immune response triggers either ITP or sarcoidosis. The disease that develops first stimulates secondary disease. After development of secondary disease, they stimulate each other. A few cases of ITP associated with sarcoidosis are well documented in English; however, the disease has rarely been reported in Korea. Here, we report on a case of ITP with sarcoidosis in a 29-year-old man. He suffered from easy bruising. The chest X-ray and the contrast-enhanced computed tomography scan showed bihilar lymphadenopathy and reticulonodular infiltrates. Bone marrow study and fluoroscopy-guided percutaneous needle biopsy were performed and the patient was diagnosed with sarcoidosis and ITP. He was put on 400 mg/kg of intravenous immunoglobulin for 5 days and administered oral steroids and further follow-up will be carried out. He has shown a good response without significant bleeding event. However, administration of more oral steroid and additional follow-up is required than for single disease, whether sarcoidosis or ITP.
Long-Term Complete Remission in an Acute Myeloid Leukemia Patient with Isolated Central Nervous System Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.
Myung Jin Kim, Sung Ae Ko, Hyo Jin Jang, Da Eun Jeong, Jeung Min Park, Kyoung Hee Lee, Min Kyoung Kim, Young Kyung Bae, Myung Soo Hyun
Yeungnam Univ J Med. 2012;29(2):96-101.   Published online December 31, 2012
DOI: https://doi.org/10.12701/yujm.2012.29.2.96
  • 1,545 View
  • 4 Download
  • 1 Crossref
AbstractAbstract PDF
Allogeneic hematopoietic stem cell transplantation (HSCT) is considered the optimal curative treatment for acute myeloid leukemia (AML), but some patients develop bone marrow relapse due to remnant leukemia, and few patients develop extramedullary relapse without bone marrow relapse. Isolated extramedullary relapse (IMER) is defined as extramedullary relapse without bone marrow relapse. IMER has been reported in various sites, including the skin, soft tissue, and central nervous system(CNS). Isolated CNS relapse is relatively rare and is associated with poor prognosis due to the absence of an optimal treatment for it. Reported herein is a case involving an adult AML woman who suffered from isolated extramedullary relapse in the CNS after allogeneic HSCT. She was treated with intrathecal chemotherapy and whole-brain and spine radiotherapy, followed by systemic chemotherapy. She is currently well, with no evidence of leukemia recurrence for over six years.

Citations

Citations to this article as recorded by  
  • Post-transplant leukemia relapse in organs: biology. and behavior in 585 reports
    Isabel Cunningham
    Critical Reviews in Oncology/Hematology.2021; 157: 103170.     CrossRef
Treatment of Hemangiopericytoma-Associated Hypoglycemia with Glucocorticoid Therapy.
Sung Woo Park, Dong Geun Kim, Myung Jin Kim, Hyo Jin Jang, Se Hoon Sohn, Sung Ae Koh, Ha Young Lee, Min Kyoung Kim, Kyoung Hee Lee, Myung Soo Hyun
Yeungnam Univ J Med. 2011;28(1):77-83.   Published online June 30, 2011
DOI: https://doi.org/10.12701/yujm.2011.28.1.77
  • 1,614 View
  • 1 Download
AbstractAbstract PDF
Non-islet cell tumor-induced hypoglycemia (NICTH) is associated with mesenchymal tumor types, including hemangiopericytoma, fibrosarcoma, mesothelioma, and neurofibroma, as well as carcinoma of the liver, adrenal glands, and kidneys. Non-islet cell tumors induce hypoglycemia by overproducing an abnormal form of insulin-like growth factor II (IGF II). Complete removal of the tumor or reduction of the tumor mass is a successful therapeutic strategy in cases of NICTH. However, if the tumor re-grows, curative resection is nearly impossible, and hypoglycemia occurs repeatedly. Glucocorticoids are effective in terms of long-term relief from hypoglycemia through promotion of gluconeogenesis in the liver, tumor suppression, production of 'big'-IGF-II, and correction of the attendant biochemical abnormalities involving the growth hormone (GH)-IGF axis. We found that administration of corticosteroid therapy to a patient suffering from NICTH resulted in improvement of hypoglycemia associated symptoms.
Paratesticular Alveolar Rhabdomyosarcoma with Multiple Lymph Nodes Metastasis Successfully Treated with Chemotherapy.
Ha young Lee, Myung Soo Hyun, Kyung Hee Lee, Min Kyoung Kim, Sung Ae Koh, Se Hoon Sohn, Sung Woo Park, Dong Geun Kim, Myung Jin Kim, Hyo Jin Jang, Mi Jin Kim
Yeungnam Univ J Med. 2011;28(1):70-76.   Published online June 30, 2011
DOI: https://doi.org/10.12701/yujm.2011.28.1.70
  • 1,483 View
  • 2 Download
AbstractAbstract PDF
Rhabdomyosarcomas are soft tissue sarcomas; while extremely rare in adults, they are one of the most common neoplasms in children and adolescents. Histologically, they can be classified into embryonal(ERMS), alveolar(ARMS), pleomorphic, and undifferentiated types. The ARMS type is very rare, and is associated with a poor prognosis. Common primary sites of ARMS are the trunk and extremities. We report on a case of paraaortic, supraclavicular, and axillary lymph node metastasis from paratesticular ARMS treated with VAC(vincristine, dactinomycin, cyclophosphamide)/ IE(ifosfamide, etoposide) chemotherapy in a young adult. Administration of six cycles of chemotherapy with VAC/ IE resulted in complete remission. The patient has maintained complete remission over the past 27 months.
Early or Late Gefitinib, Which is Better for Survival?: Retrospective Analysis of 228 Korean Patients with Advanced or Metastatic NSCLC.
Dong Gun Kim, Min Kyoung Kim, Sung Hwa Bae, Sung Ae Koh, Sung Woo Park, Hyun Je Kim, Myung Jin Kim, Hyo Jin Jang, Kyung Hee Lee, Kwan Ho Lee, Jin Hong Chung, Kyung Chul Shin, Hun Mo Ryoo, Myung Soo Hyun
Yeungnam Univ J Med. 2011;28(1):31-44.   Published online June 30, 2011
DOI: https://doi.org/10.12701/yujm.2011.28.1.31
  • 1,525 View
  • 2 Download
AbstractAbstract PDF
BACKGROUND
The optimal timing of treatment with EGFR-tyrosine kinase inhibitors (EGFR-TKI) in NSCLC patients has not yet been determined. METHODS: We separated 228 patients with advanced/metastatic NSCLC treated with gefitinib into an early gefitinib group (patients who received gefitinib as first- or second-line treatment) and a delayed gefitinib group (patients who received gefitinib as third or fourth-line treatment) and attempted to determine whether the timing of gefitinib treatment affected clinical outcomes. RESULTS: Median overall survival (OS), progression free survival (PFS), and median OS from first-line treatment of advanced/metastatic disease (OSt) for 111 patients in the early gefitinib group were 6.2 months, 3.3 months, and 11.6 months. However, median OS, PFS, and OSt for 84 patients in the delayed gefitinib group were 7.8 months, 2.3 months, and 22.7 months. No differences in OS and PFS were observed between the 2 groups. However, OSt was significantly longer in the delayed gefitnib group. Timing of gefitinib therapy was one of the independent predictors of OSt. Hb > or = 10 g/dl, and having never smoked, and ECOG performance status < or =1 were independent predictors of better PFS. CONCLUSION: Deferral of gefitinib therapy in patients with advanced or metastatic NSCLC may be preferable if they are able to tolerate chemotherapy.
Comparative Study on the Infection Rates of Protected Environment versus Non-Protected Environment in Acute Myeloid Leukemia during Remission Induction Chemotherapy.
Se Hoon Sohn, Ha young Lee, Dong Geun Kim, Sung Woo Park, Myung Jin Kim, Myung Jin Oh, Hye Deok Woo, Hun Mo Ryoo, Sung Hwa Bae, Kyung Hee Lee, Min Kyoung Kim, Myung Soo Hyun
Yeungnam Univ J Med. 2010;27(2):113-121.   Published online December 31, 2010
DOI: https://doi.org/10.12701/yujm.2010.27.2.113
  • 1,605 View
  • 5 Download
AbstractAbstract PDF
BACKGROUND
AND PURPOSE: Patients with acute leukemia experience prolonged periods of neutropenia due to their disease or its treatment. For this reason, they often develop serious infectious complications. Although antibiotic therapy has improved in recent years, the fatality rate from infection remains high. For the control of infection, protected environment was developed. But because of economic issue, most of chemotherapy with acute myeloid leukemia have conducted in non-protected environment. So this study compared the rate of complete remission, days with neutropenia, rate of fever, rate of positive culture, rate of overt infection and use of antibacterial and antifungal agents with patients within non-protected environment and protected environment, retrospectively. Patients with acute myeloid leukemia during first remission induction chemotherapy were eligible for this study. METHODS: Retrospective analysis was conducted between patients in non-protected (25 patients) and protected environment (14 patients) with acute myeloid leukemia during remission induction chemotherapy. RESULTS: Rate of overt infection, rate of fever, rate of positive culture and rate of use of antibiotics were significantly high in patients within non-protected environment compared with patients within protected environment. There were no differences in rate of complete remission and days of neutropenia. CONCLUSIONS: This study suggests protected environment for patients with acute myeloid leukemia during remission induction chemotherapy could reduce rate of overt infection, and rate of use of antibiotics.
A Case of Tarsal Bone Tuberculosis in a Patient with Polycythemia Vera.
Sung Ae Koh, Se Hun Shon, Dong Gun Kim, Sung Woo Park, Choong Ki Lee, Kyung Hee Lee, Min Kyoung Kim, Myung Soo Hyun
Yeungnam Univ J Med. 2009;26(1):44-48.   Published online June 30, 2009
DOI: https://doi.org/10.12701/yujm.2009.26.1.44
  • 1,591 View
  • 0 Download
AbstractAbstract PDF
Talus tuberculosis is a rare disease, even in an endemic tuberculosis area. In reviews of the worldwide literature, only 18 cases of talus tuberculosis have been reported. Recently, we experienced a case of a 70-year-old polycythemia vera patient with right metatarsopharyngeal joint pain for 2 months duration who was diagnosed with talus tuberculosis with prostate involvement. Tuberculosis should be considered as one of the causes of monoarticulitis, especially in countries, where the disease is endemic. Additionally, we highly recommend taking a biopsy of the site of suspected infection because an early diagnosis is the key to successful treatment.
A Case of Multiple Myeloma with AL Amyloidosis Successfully Treated with Autologous Stem Cell Transplantation
Ha-young Lee, Kyung Hee Lee, Min Kyoung Kim, Hee Soon Cho, Myung Soo Hyun
Yeungnam Univ J Med. 2007;24(2 Suppl):S676-682.   Published online December 31, 2007
DOI: https://doi.org/10.12701/yujm.2007.24.2S.S676
  • 1,032 View
  • 3 Download
AbstractAbstract PDF
Myeloma is a disease of neoplastic B lymphocytes that synthesize abnormal amounts of immunoglobulin (Ig) or Ig fragments. Ten to twenty percent of myeloma patients are known to develop clinical evidence of amyloid-light chain(AL) amyloidosis. A high index of suspicion, however, is needed to make a diagnosis of amyloidosis. We report a case of multiple myeloma with AL amyloidosis successfully treated with autologous stem cell transplantation. In our case, the patient presented with longstanding abdominal discomfort and anterior chest pain. Chest X-ray showed several osteolytic changes on ribs. Endoscopic biopsy revealed massive amyloid deposits in the wall of stomach and rectum. Serum/urine protein electroporesis and bone marrow biopsy confirmed the diagnosis of multiple myeloma. At 18 months after high dose chemotherapy and autologous stem cell transplantation(ASCT), the patient maintained a complete response. In patients with multiple myeloma with AL amyloidosis, high dose chemotherapy and ASCT can be effective treatment strategy.
Acute Myeloid Leukemia with t(8;21)(q22;q22) (AML1/ETO) in a Patient with Marked Hypocellularity and Low Blasts Count.
Sung Ho Chun, Hee Soon Cho, Chae Hoon Lee, Kyung Dong Kim, Min Kyoung Kim, Myung Soo Hyun, Soon Il Jung
Yeungnam Univ J Med. 2007;24(1):85-90.   Published online June 30, 2007
DOI: https://doi.org/10.12701/yujm.2007.24.1.85
  • 1,423 View
  • 1 Download
AbstractAbstract PDF
According to the World Health Organization (WHO) classification system, cases with t(8;21)(q22;q22) should be diagnosed as acute myeloid leukemia (AML) even with a blast count of less than 20 percent in blood or bone marrow. It is an uncommon manifestation, moreover hypocellularity is rarely observed in this subtype of leukemia. Here, we report a case of t(8;21) in a patient with marked hypocellularity of less than 5 percent and a blast count of less than 20 percent. This patient responded relatively well to chemotherapy. An allogeneic bone marrow transplantation was performed with good engraftment . This case suggests that hypocellular AML with a t(8;21) has as good a prognosis as hypercellular AML with t(8;21).
A Case of Congenital Factor VII Deficiency Presented with Subacute Subdural Hematoma.
Min Kyoung Kim, Sang Jun Shin, Kyung Ok Kim, Kyung Hee Lee, Myung Soo Hyun, Hee Soon Cho
Yeungnam Univ J Med. 2004;21(2):231-236.   Published online December 31, 2004
DOI: https://doi.org/10.12701/yujm.2004.21.2.231
  • 1,733 View
  • 3 Download
  • 2 Crossref
AbstractAbstract PDF
A congenital factor VII deficiency is a rare disorder with an estimated incidence in the western contries of one in 500, 000. Because factor VII is important in initiation the coagulation cascade, a factor VII deficiency can result in significant bleeding with prolongation of the prothrombin time. We present a case of a factor VII deficiency with a subdural hematoma in an 18-year-old boy whose plasma activity of factor VII was < or =10%. Previously, he did not have any symptoms, such as hemarthrosis, easy bruising or bleeding after a minor trauma. He was administered fresh frozen plasma and a trephination was performed. His sister also had 51% lower level of factor VII.

Citations

Citations to this article as recorded by  
  • A forgotten or minimized head trauma, rather than a mild FVII deficiency, is the most likely cause of a subdural hematoma
    A. Girolami, S. Ferrari, E. Cosi, A.M. Lombardi
    Blood Cells, Molecules, and Diseases.2016; 60: 73.     CrossRef
  • A case of intracranial hemorrhage in a neonate with congenital factor VII deficiency
    Won Seok Lee, Young Sil Park
    Korean Journal of Pediatrics.2010; 53(10): 913.     CrossRef
Evaluation of short-term Hypolipidemic Effect and Safety of Simvastatin(Zocor(R)) in Patients with Hyperlipidemia.
Min Kyoung Kim, Yong Ho Park, Jong sun Park, Dong Gu Shin, Young Jo Kim, Gi Sik Kim
Yeungnam Univ J Med. 2003;20(2):152-159.   Published online December 31, 2003
DOI: https://doi.org/10.12701/yujm.2003.20.2.152
  • 1,587 View
  • 6 Download
  • 1 Crossref
AbstractAbstract PDF
BACKGROUND
Hyperlipidemia is the one of the major risk factors causing the atherosclerosis of coronary arteries. Treatment of hyperlipidemia with drugs has been confirmed the effects of therapy showing a decreased incidence of coronary artery disease. Simvastatin is a new drug of HMG-CoA reductase inhibitors and the short-term hypolipidemic effects and safety of simvastatin is evaluated in patients with hyperlipidemia. METHODS: We studied 63 patients (39 males and 24 females, mean age 58) for 12 weeks whose plasma levels of total cholesterol were higher than 240 mg/dL or higher than 220 mg/dL with ischemic heart disease. Simvastatin was administered 20 mg/day and measured lipid profile at 12 week interval. RESULT: 1)Simvastatin significantly reduced the level of the plasma total cholesterol(-29.3%), LDL- cholesterol(-36.9%) and triglyceride(-13%)(p<0.05) but the level of HDL-cholesterol was not changed after 12 weeks simvastatin therapy. 2)the clinical symptoms and laboratory examination before and after simvastatin treatment showed no particular abnormal findings in short term follow up. CONCLUSION: These results suggested that short-term simvastatin therapy in patients with hyperlipidemia seeems to be very effective and safe.

Citations

Citations to this article as recorded by  
  • A Population Pharmacokinetic–Pharmacodynamic Model for Simvastatin that Predicts Low‐Density Lipoprotein‐Cholesterol Reduction in Patients with Primary Hyperlipidaemia
    Jimyon Kim, Byung‐Jin Ahn, Hong‐Seok Chae, Seunghoon Han, Kichan Doh, Jeongeun Choi, Yong K. Jun, Yong W. Lee, Dong‐Seok Yim
    Basic & Clinical Pharmacology & Toxicology.2011; 109(3): 156.     CrossRef

JYMS : Journal of Yeungnam Medical Science